Small Pharma Inc (OP:DMTTF)

N/A UNCHANGED

Last Price Updated: 3:59 PM EDT, Oct 20, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Small Pharma Inc

< Previous 1 2 3 4 5 6 7 8 Next >

Small Pharma Reports Fiscal First Quarter 2024 Highlights

July 27, 2023

From Small Pharma Inc.

Via GlobeNewswire

Psyched: Australia's Innovative Program, Congressional Amendments, Therapy Reimbursement And More ↗

July 11, 2023

First Country Allowing MDMA & Psilocybin For Depression, PTSD Makes Headlines On Saturday, July 1, 2023, Australia became the first country to allow physicians to prescribe MDMA to treat post-traumatic...

Via Benzinga

Small Pharma Implements Costs Cut: New R&D Strategy And Management Team Change ↗

July 05, 2023

Together with reporting its annual financial results and pipeline update, short-acting psychedelics developer Small Pharma Inc. (OTCQB: DMTTF) stated its intentions to

Via Benzinga

Small Pharma Announces SPL028 R&D Strategy Update

July 05, 2023

From Small Pharma Inc.

Via GlobeNewswire

Small Pharma Announces Management Team Change

July 05, 2023

From Small Pharma Inc.

Via GlobeNewswire

Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More ↗

July 04, 2023

World's Largest Psychedelics Conference Boasts 12K Attendees

Via Benzinga

Small Pharma Implements Cost-Cutting Strategy To Reduce Cash Burn As Trial Progresses ↗

June 29, 2023

UK-based biotech firm Small Pharma Inc. (OTCQB: DMTTF) shared its financial outcomes for the fiscal year ended Feb. 28, plus pipeline updates. Highlights:

Via Benzinga

Small Pharma Reports Financial Results for the Fiscal Year Ended February 28, 2023 and Recent Business Highlights

June 28, 2023

From Small Pharma Inc.

Via GlobeNewswire

Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More ↗

May 31, 2023

Microdosing LSD For Major Depression Treatment Seeks Further Clinical Validation Via New Study Australian psychedelics company MindBio Therapeutics Corp. was granted approval by both the Ethics...

Via Benzinga

Small Pharma's IP Portfolio Grows With Numerous Approved Patent Applications Around The World ↗

May 26, 2023

U.K.-based short-acting psychedelics developer Small Pharma Inc. (OTCQB: DMTTF) has been working hard on securing a proprietary IP throughout North America, Australasia and Europe.

Via Benzinga

Small Pharma Announces Significant Developments In Intellectual Property Portfolio

May 25, 2023

5 new patent grants, 3 expected upcoming patent grants, and 8 notices of allowance in key international jurisdictions

From Small Pharma Inc.

Via GlobeNewswire

Small Pharma to Present at Upcoming CINP World Congress of Neuropsychopharmacology

May 03, 2023

Chief Medical and Scientific Officer, Dr. Carol Routledge, will deliver a poster presentation on data from the Company’s SPL026 Phase IIa clinical trial in patients with Major Depressive Disorder

From Small Pharma Inc.

Via GlobeNewswire

DMT For Major Depression Shows Remarkable Benefits After Six-Month Trial ↗

April 04, 2023

Short-acting psychedelics company Small Pharma Inc.

Via Benzinga

Small Pharma Announces Positive Six-month Data from Phase IIa Trial of SPL026

April 04, 2023

Approximately two-thirds of trial patients with Major Depressive Disorder achieving remission following SPL026 treatment sustained remission to six-months

From Small Pharma Inc.

Via GlobeNewswire

EXCLUSIVE: NYC Ketamine Center Co-Founder On Prices, Insurance, Competition & Expansion ↗

March 21, 2023

This is the third article of a three-part series, you can find the first and

Via Benzinga

Psyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & More ↗

March 13, 2023

Major Depressive Disorder: Small Pharma’s Phase 2 DMT Trial, BetterLife’s Preclinical LSD Trial

Via Benzinga

Major Psychedelics VC & EFT Directors Will Share Valuable Insights At Upcoming Benzinga Event ↗

March 13, 2023

The Benzinga Psychedelics Capital Conference (PCC) is rapidly becoming the place to be for all those interested or involved in the space. In addition to being the place where deals are done, you'll...

Via Benzinga

Small Pharma Inc: Positive Clinical Data For Major Depressive Disorder, Upcoming Virtual Roundtable ↗

March 08, 2023

Short-acting psychedelics biotech company Small Pharma Inc. (OTCQB: DMTTF) shared positive outcomes from its Phase 2a study of SPL026, the first placebo-controlled trial of the DMT-based short-duration...

Via Benzinga

Small Pharma to Host Virtual Roundtable Event with Key Opinion Leaders in Psychiatry

March 07, 2023

From Small Pharma Inc.

Via GlobeNewswire

Small Pharma Announces Further Positive Data from SPL026 Phase IIa Trial in Major Depressive Disorder Strengthening Topline Efficacy Results

March 07, 2023

From Small Pharma Inc.

Via GlobeNewswire

Small Pharma to Present at Cowen’s 43rd Annual Health Care Conference

March 01, 2023

Company will also host a cocktail reception on Tuesday, March 7

From Small Pharma Inc.

Via GlobeNewswire

Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More ↗

February 21, 2023

Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, New Hampshire's Setback Earlier this week, three bills were introduced and...

Via Benzinga

Short-Acting Psychedelics: DMT-Based Drug Therapy Gets Tested In New Clinical Trial ↗

February 15, 2023

Psychedelics biotech company Small Pharma Inc. (OTCQB: DMTTF) has dosed the first subject in its first-in-human clinical trial assessing proprietary DMT drug SPL028 paired with supportive therapy.

Via Benzinga

First Subject Dosed in Small Pharma’s First-in-Human Phase I Clinical Trial with SPL028

February 15, 2023

From Small Pharma Inc.

Via GlobeNewswire

Race Is On For Psychedelic DMT-Related Compounds, Small Pharma, Inc To Issue Two New Patents ↗

February 01, 2023

After the positive results provided by its clinical trial assessing novel DMT’s effects on patients with Major Depressive Disorder (MDD), psychedelics biotech Small Pharma Inc.

Via Benzinga

Small Pharma Announces Update on Intellectual Property Portfolio with Two New Patents Approved for Issue

February 01, 2023

From Small Pharma Inc.

Via GlobeNewswire

Small Pharma, Inc's Psychedelics For Major Depression Trial Results And Q1 Earnings ↗

January 25, 2023

Short-acting psychedelics biotech Small Pharma Inc. (OTCQB: DMTTF)’s proprietary intravenous (IV) DMT-based drug SPL026 delivered positive topline results in a Phase 2a trial for the treatment of Major...

Via Benzinga

Small Pharma Reports Fiscal Third Quarter 2023 Highlights

January 25, 2023

Small Pharma Inc. (TSXV:DMT) (OTCQB:DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental

Via PressReach

Small Pharma Reports Fiscal Third Quarter 2023 Highlights

January 25, 2023

From Small Pharma Inc.

Via GlobeNewswire

Small Pharma Reports Positive Top-line Results from Phase IIa Trial of SPL026 in Major Depressive Disorder

January 25, 2023

From Small Pharma Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.